-10% in Three Days: What Really Happened with BRO
There are weeks when the market does exactly what you didn’t expect, and the week following Brown & Brown’s BRO 0.00%↑ Q1 2026 earnings report was one of them.
The stock fell roughly 9–12% in the days after the April 28th results, with an initial hit of approximately –4.5% the day after the announcement.
For anyone not closely following the company, the headline looks like a red flag.
For those who do follow it, the reaction raises a different question: what is the market pricing in that the results aren’t confirming?
My read is that this isn’t a business deterioration — it’s a multiple compression, accelerated by expectations the market had built too high and by signals that, read through a negative lens, feed the “deceleration” narrative. I want to walk through each of those signals carefully.
Let’s dig in.
Overall Snapshot of the Quarter
The surface-level numbers are good.
BRO reported total revenues of $1.9 billion, a 35.4% increase versus Q1 2025.
Adjusted EBITDAC reached $731 million, growing 36.6%, and the adjusted EBITDAC margin improved 40 basis points to 38.5%. Operating cash generation exceeded $260 million, a 23% increase from the prior year.
Where ambiguity creeps in is EPS. GAAP diluted earnings per share came in at $1.06, a 7.8% decline versus the $1.15 from the prior year. At the same time, adjusted EPS was $1.39, also growing 7.8%.
That divergence between the GAAP and adjusted figures creates a contradictory message that makes it easy to build a negative narrative: if someone is looking for a reason to sell, they have one. If someone understands that the difference stems from intangible amortization tied to Accession, integration costs, and mark-to-market on an escrow, the story looks completely different.
The market, in the hours immediately following a report, tends to anchor on the headline — almost always.
Quality of Growth: Organic vs. Total
This is the central point of the conversation, and the one I believe explains more than any other the market’s reaction.
Total growth of 35% is spectacular, but almost entirely acquisition-driven.
Organic growth was exactly 0%; organic including contingents was +2.2%.
When I wrote about Q4 2025, I already flagged this pattern: the year closed with 35.7% total growth but –2.8% organic, distorted by the prior year’s flood claims processing revenue base.
What we’re seeing in Q1 2026 is a continuation of that same dynamic: the company is growing strongly in absolute terms, but the organic engine — the one that reflects how well it’s generating new business in the market — remains modest.
The company explains it correctly: prior-year flood revenues created a headwind of nearly 100 basis points on organic growth, and catastrophic property rates fell more than anticipated. But for the market, explanations are a luxury it doesn’t always take the time to absorb.
What it sees is a company that grew organically 0% while its larger peers are posting higher figures. That gap, even if partly explainable and partly temporary, is enough to justify a re-rating.
Segment Performance
Retail
In the Retail segment, revenues grew 33.4% with organic growth of 1.0% (or 1.3% including contingents).
There are several simultaneous pressures:
Declining property rates
A revenue model shift in a pharmacy consulting business from a volume-based to a PEPM structure
And a reduction in net new business for the quarter.
The segment’s adjusted EBITDAC margin fell 130 basis points to 36%, largely due to the seasonal weight of Accession (Risk Strategies) versus the legacy Brown & Brown book, which is historically more profitable in Q1 due to the concentration of Employee Benefits business.
Specialty Distribution
In Specialty Distribution, the read is more positive than the headline number suggests.
Revenues grew 40%, organic excluding contingents was –2.0%, but including contingents it was +3.9%.
The –2.0% has a concrete explanation: in Q1 2025, the segment had recognized $12 million in non-recurring revenue from flood claims processing. Strip that out and the underlying business is growing well.
Additionally, the segment’s adjusted EBITDAC margin improved 30 basis points to 40.8%, driven by strong contingent growth.
This is a segment that knows how to preserve profitability even when the rate cycle isn’t working in its favor.
Contingents and Revenue Stability
Contingents are one element of BRO’s model I discuss most with my followers, because they’re hard to value from the outside and easy to dismiss as “variable income.”
In Q1, total contingents grew by $54 million: $22 million from Accession operations and $30 million from underwriting profitability in the legacy business. This is a direct result of falling E&S property rates: when carriers make more money, BRO’s contingents go up.
Management made the decision to introduce a new metric, “Organic Revenue with Contingents,” precisely to help the market understand this inverse correlation between rates and contingents.
It’s a strategic move: if the market insists on penalizing organic growth excluding contingents, BRO wants to offer an alternative denominator that more faithfully reflects its actual economic model.
CFO Andy Watts explained it clearly on the call: the ability to generate contingents is a structural part of the business, not a fortunate accident.
The problem is that investors approaching BRO from a more conventional lens will continue to watch “pure” organic growth, and any effort by management to reframe the conversation takes time to sink in.
Accession Integration and M&A
Accession is the big bet of the past twelve months, and Q1 results show it’s tracking to plan — albeit with the expected short-term cost.
The integration contributed approximately $445 million in revenues for the quarter, but due to the seasonal effect and the acquired business’s mix, it diluted the consolidated EBITDAC margin by roughly 200 basis points.
In my Q4 2025 analysis, I already flagged this dynamic: Accession carries a margin profile of around 35% for the full year, below the legacy BRO business’s historical margin in early quarters when Employee Benefits carries more weight.
The company maintains its guidance of $30–40 million in EBITDA synergies for 2026, with full integration expected toward 2028. Visible integration costs in the quarter were $26 million, and the Accession escrow mark-to-market added another $64 million in non-cash expense that distorts the GAAP figure.
The market tends to be impatient with integrations. It wants to see synergies before they materialize and penalizes dilution before it’s offset. My read is that the process is on track, but the market is right to demand evidence quarter by quarter.
Additionally, over the past six months, BRO repurchased approximately 5 million shares for $350 million, with $250 million deployed specifically in Q1. Combined with the declared dividend of $0.165 per share (+10% year-over-year), capital allocation remains disciplined and shareholder-oriented. But in an environment where the multiple is demanding and organic growth is under pressure, buybacks alone won’t stop an expectations reset.
Idiosyncratic Growth Headwinds
There are two company-specific factors weighing on organic growth that deserve to be distinguished from the “core business.”
The first is the model transition in the pharmacy consulting business: the shift from a volume-based to a PEPM structure will pressure organic growth by 50–100 basis points over the coming quarters. It’s a strategic decision Powell Brown defends as correct for the long term, but in the short term it creates an accounting “hole” in the metrics the market watches most closely.
The second is the legal situation with the startup broker.
As of the end of March, clients representing approximately $31 million in annualized revenues had already moved to competitors, up from the $23 million reported the prior quarter.
BRO has an active TRO (temporary restraining order) in Massachusetts limiting the startup’s ability to continue poaching clients, and the CFO indicated that sequential growth in that figure should moderate. But while litigation plays out, there’s real impact on organic growth in the Retail segment.
Neither of these factors represents a permanent deterioration of the model. Both are temporary, quantifiable, and already being managed. The key for my investment thesis is knowing how to distinguish them from systemic noise — something I explored in the context of idiosyncratic risk management in this analysis: when a quality business faces specific, contained pressures, the right question isn’t whether to exit, but whether the long-term thesis remains intact.
Have you read my latest Deep Dive yet?
In-depth analysis and rating of the companies I follow.
Insurance Market Environment
The context in which BRO operates is key to calibrating organic growth expectations over the coming quarters.
In admitted markets, commercial P&C rates sit in the flat to +5% range, workers’ comp between flat and –3%, non-cat property between –5% and +5%, and casualty with increases of 2–5% in primary layers and materially more in excess layers.
Employee benefits remains the segment with the most rate inflation, with medical costs rising 8–10% and pharmacy above 10%.
The most relevant shift is in E&S property.
Catastrophic property renewals in Q1 were placed at rate declines of 15–35%, and management acknowledged the magnitude was larger than anticipated. This hits Specialty Distribution directly, which has historically carried heavy weighting toward cat property.
The good news is that the addition of One80 (part of Accession) will rebalance this mix toward casualty over time, reducing sensitivity to the property cycle.
For Q2, management anticipates “flat” organic growth in Specialty Distribution, as it’s the quarter with the highest concentration of cat property placements, followed by gradual improvement in the second half as One80 enters the organic calculation and the mix shifts.
The second half of 2026 is, narratively, the inflection point the market needs to see in order to regain confidence in organic growth.
Technology and AI Strategy
One of the topics that occupied the most space in the Q1 presentation was the technology and artificial intelligence strategy — and I don’t think that’s a coincidence: management wants the market to understand that BRO isn’t just an insurance broker, but a distribution platform with a growing technological edge.
They’ve spent more than ten years building the data infrastructure that now allows them to deploy AI in a scalable, measurable way.
Tangible results include AI agents that automate more than 25% of the submissions process in wholesale and programs, and a proprietary billing platform that already saves more than 50,000 hours annually. In retail, policy verification agents reduce E&O exposure and improve the client experience.
What strikes me most about Powell Brown’s framing is his emphasis on AI as an amplifier of the model, not a disruptor. BRO isn’t in the business of small, standardized accounts that are most susceptible to disintermediation; its strength lies in complex risks, where long-term advisory relationships with carriers remain the differentiating asset.
That protects the model from the most obvious automation threats and turns AI investment into a lever for efficiency and capacity — not an existential bet.
Management Messaging and Qualitative Guidance
Powell Brown described Q1 results as “good” and spoke of continuity with the “industry-leading” performance of 2025.
That is, of course, CEO language.
But if you look beneath the rhetoric, the data supports the narrative: operating cash flow above $260 million, 14% cash conversion ratio, adjusted EBITDAC margin of 38.5%, adjusted EPS growing roughly 8%.
Qualitative guidance for the rest of the year calls for modest but sequential improvement in organic growth, with an upper bound of around 2.5% toward year-end.
That’s not aggressive guidance.
It doesn’t invite enthusiasm. But it’s consistent with a pricing environment that continues to normalize and an Accession integration still in progress. The recovery of organic growth won’t be an event — it will be a trajectory.
The Market’s Reaction
The question I’m left with at the close of this analysis is whether the selloff is justified or an opportunity.
And my answer is that it’s partially both.
The market is right to demand more organic growth from a company trading at a premium multiple relative to peers. It’s right to question whether the Accession integration is diluting more than expected and for how long. It’s right to ask whether the catastrophic property environment will continue to pressure results or whether we’ll see a bounce after hurricane season.
But the market is not right when it penalizes as if this were permanent deterioration what is, in large part, a combination of well-documented temporary factors:
Difficult year-over-year comparisons
Non-recurring integration costs
Business model transitions still in progress, and
Rate pressure in one specific line that management itself identifies as the point of maximum near-term stress.
BRO remains the same business that has compounded capital consistently for years: high margins, robust cash generation, a resilient decentralized model, and a management team that has shown discipline through every cycle.
The selloff of recent weeks doesn’t change that. What it does change is the entry point for anyone who hadn’t had a second chance in quite some time.
This analysis represents a personal opinion based on a review of the company’s public reports and does not constitute investment advice.